Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
78.64
+0.73 (+0.94%)
Streaming Delayed Price
Updated: 3:35 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2%
August 01, 2024
The Bank of England cuts interest rate for first time in over 4 years to 5%, citing inflation below target and emerging economic slack. Pound falls, UK stocks hold steady.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Via
InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
July 29, 2024
From
AstraZeneca
Via
Business Wire
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
July 26, 2024
AstraZeneca CEO Pascal Soriot urges the UK government to reassess drug funding after NICE deems Enhertu too costly, highlighting concerns over new methodology affecting advanced cancer treatments and...
Via
Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
July 26, 2024
These stocks arguably deserve more respect from investors.
Via
The Motley Fool
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
July 26, 2024
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu.
Via
MarketBeat
Topics
ETFs
7 Explosive Growth Stocks Set to Soar in 2024
July 25, 2024
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024.
Via
InvestorPlace
Why AstraZeneca Stock Is Sliding Today
July 25, 2024
The British drugmaker's Q2 results were good, but seemingly not good enough for many investors.
Via
The Motley Fool
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
July 25, 2024
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown.
Via
Benzinga
Topics
Economy
Exposures
Economy
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
July 25, 2024
AZN earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook
July 25, 2024
The company no longer expects its earnings to decline this year. Instead, AstraZeneca called for stable profit.
Via
Investor's Business Daily
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
July 25, 2024
AstraZeneca's Q2 sales rose 13% to $12.94 billion, beating expectations. Oncology sales grew 15% to $5.33 billion. Notable drug performances include Tagrisso up 8%, Calquence up 21%, and Farxiga up...
Via
Benzinga
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
July 25, 2024
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.
Via
Benzinga
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
July 25, 2024
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech...
Via
Benzinga
Topics
Government
Stocks
Exposures
Political
US Equities
AstraZeneca’s H1 and Q2 2024 Financial Results
July 25, 2024
From
AstraZeneca
Via
Business Wire
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q2 2024
July 25, 2024
AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
July 25, 2024
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
Via
InvestorPlace
American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday
July 25, 2024
Via
Benzinga
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
July 23, 2024
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints.
Via
Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
July 23, 2024
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.
Via
Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
July 22, 2024
It was another wild week for the market as it had to contend with a lot of news.
Via
Talk Markets
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
July 22, 2024
The big pharma company's top drug is losing ground, but its dividend keeps rising.
Via
The Motley Fool
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
July 21, 2024
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.
Via
Benzinga
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
Via
Benzinga
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
Exposures
COVID-19
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
July 15, 2024
Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market.
Via
InvestorPlace
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
July 10, 2024
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside.
Via
InvestorPlace
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
July 05, 2024
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election.
Via
Benzinga
Topics
ETFs
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.